Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Upcoming)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
mTOR regulates T cell exhaustion and PD-1–targeted immunotherapy response during chronic viral infection
Satomi Ando, … , Rafi Ahmed, Koichi Araki
Satomi Ando, … , Rafi Ahmed, Koichi Araki
Published November 15, 2022
Citation Information: J Clin Invest. 2023;133(2):e160025. https://doi.org/10.1172/JCI160025.
View: Text | PDF
Research Article Immunology Infectious disease

mTOR regulates T cell exhaustion and PD-1–targeted immunotherapy response during chronic viral infection

  • Text
  • PDF
Abstract

T cell exhaustion is a state of T cell dysfunction associated with expression of programmed death 1 (PD-1). Exhausted CD8+ T cells are maintained by self-renewing stem-like T cells that provide differentiated TIM3+ cells, a part of which possesses effector-like properties. PD-1–targeted therapies enhance T cell response by promoting differentiation of stem-like T cells toward TIM3+ cells, but the role of mTOR during T cell exhaustion remains elusive. Here, we showed that mTOR inhibition has distinct outcomes during the beginning of and after the establishment of chronic viral infection. Blocking mTOR during the T cell expansion phase enhanced the T cell response by causing accumulation of stem-like T cells, leading to improved efficacy of PD-1 immunotherapy; whereas, after exhaustion progressed, mTOR inhibition caused immunosuppression, characterized by decreased TIM3+ cells and increased viral load with minimal changes in stem-like T cells. Mechanistically, a cell-intrinsic mTOR signal was vital for differentiation of stem-like T cells into the TIM3+ state in the early and late phases of chronic infection as well as during PD-1 immunotherapy. Thus, PD-1 blockade worked after cessation of mTOR inhibition, but simultaneous treatment failed to induce functional TIM3+ cells, reducing efficacy of PD-1 immunotherapy. Our data demonstrate that mTOR regulates T cell exhaustion and have important implications for combination cancer therapies with PD-1 blockade.

Authors

Satomi Ando, Charles M. Perkins, Yamato Sajiki, Chase Chastain, Rajesh M. Valanparambil, Andreas Wieland, William H. Hudson, Masao Hashimoto, Suresh S. Ramalingam, Gordon J. Freeman, Rafi Ahmed, Koichi Araki

×

Figure 1

mTOR inhibition enhances CD8+ T cell response by promoting the formation of stem-like CD8+ T cells during the early phase of chronic infection.

Options: View larger image (or click on image) Download as PowerPoint
mTOR inhibition enhances CD8+ T cell response by promoting the formation...
Mice were infected with LCMV clone 13 in the presence or absence of rapamycin treatment. Rapamycin was injected i.p. every day from day –1 to day 30–35 (1 month) after infection. LCMV-specific CD8+ T cell response was examined on days 10 and 31–36 (1 month) after infection. (A) The total number of DbGP33 tetramer+, DbGP276 tetramer+, and PD-1+CD8+ T cells in the spleen at 10 days and 1 month after infection (n = 8 per each group for 10 days, n = 9 per each group for 1 month). Flow cytometry plots, gated on total live splenocytes, show the frequency of DbGP33 tetramer+ CD8+ T cells 1 month after infection. (B) Phenotypic analysis of LCMV-specific DbGP33 tetramer+ CD8+ T cells in the spleen at 1 month after infection. (C) The frequency of stem-like (TIM3–TCF1+) and TIM3+ more-differentiated (TIM3+TCF1–) LCMV-specific CD8+ T cells in the spleen at 1 month after infection. The flow cytometry plots were gated on DbGP33 tetramer+ CD8+ T cells. (D) The number of TIM3+ differentiated (TIM3+TCF1–) or (E) stem-like (TIM3–TCF1+) CD8+ T cells in the spleen is shown for DbGP33 tetramer+, DbGP276 tetramer+, and PD-1+CD8+ T cells (n = 8 per each group for 10 days, n = 9 per each group for 1 month). Each symbol represents an individual mouse. Each line represents geometric means, and P values were calculated by unpaired t test. Data were pooled from 2 or 3 independent experiments.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts